Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

This was the stock's second consecutive day of losses.

Shares of Viatris (NASDAQ:VTRS) added ~5% in the premarket on Thursday after the company said that two pivotal Phase 3 trials ...

Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow morning. Here’s what you need to know.

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

May 8 (Reuters) - Viatris' (VTRS.O), opens new tab fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, the company said on Thursday, adding that it would ...

Good morning, everyone, and welcome to the Viatris Q1 2025 earnings call. (Operator Instructions) Please also note, today's event is being recorded. At this time, I'd like to turn the floor over to ...